Welcome to our dedicated page for Insulet SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Insulet Corporation (NASDAQ: PODD) SEC filings, offering a structured view of the company’s regulatory disclosures as a NASDAQ-listed medical device manufacturer. Insulet develops the Omnipod tubeless insulin pump platform and the Omnipod 5 Automated Insulin Delivery System, and its filings help investors understand how this business is governed, financed, and overseen.
Through Forms 10-K and 10-Q, Insulet reports audited and interim financial statements, risk factors, and management’s discussion of its Omnipod product platform, manufacturing operations, and growth strategy in automated insulin delivery and related drug delivery applications. Current reports on Form 8-K disclose material events such as quarterly financial results, amendments to incentive and severance plans, executive leadership transitions, and appointments to the board of directors and committees.
Investors can also review proxy statements for details on executive and director compensation, governance structures, and shareholder matters, as well as any registration statements related to securities offerings. For monitoring insider activity, Forms 3, 4, and 5 report beneficial ownership and changes in holdings by Insulet’s officers, directors, and other insiders, which some investors use to gauge management’s alignment with shareholders.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify important changes in financial performance, risk disclosures, compensation arrangements, or governance. Real-time updates from the SEC’s EDGAR system ensure that new Insulet filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider transaction reports, appear promptly, while AI-generated explanations make complex regulatory language more accessible to a broad range of investors and researchers.
Insulet Corp EVP and CCO Michael Panos received new equity awards. He was granted an employee stock option covering 7,255 shares of common stock at an exercise price of $207.04 per share, expiring on April 1, 2036. These non-qualified stock options become exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date.
He also received 2,777 restricted stock units that vest in substantially equal installments on each of the first, second and third anniversaries of the grant date and are settled one-for-one in common shares. Following these grants, he directly holds 2,782 shares of common stock and 7,255 stock options.
INSULET CORP executive Michael Panos filed an initial Form 3 reporting his holdings in the company. As EVP and Chief Commercial Officer, he disclosed direct beneficial ownership of 5 shares of INSULET CORP Common Stock. This filing records his starting equity position as an insider, without indicating any recent buy or sell transaction.
INSULET CORP director Robert Luther Huffines received an award of 111 deferred common stock units of Insulet common stock on March 31, 2026, valued at $209.84 per unit. This grant was made in lieu of cash board compensation under the company’s Deferred Compensation Plan for Non-Employee Directors and increased his reported holdings to 638 shares or units.
The deferred common stock units will convert into the same number of Insulet common shares upon distribution, with any fractional share value paid in cash. Distribution occurs at the director’s election, either in a lump sum or in substantially equal annual installments, consistent with the plan’s terms.
The Vanguard Group filed Amendment No. 14 to Schedule 13G/A reporting that it beneficially owns 0 shares of Insulet Corp Common Stock, representing 0% of the class as disclosed in the amendment.
The amendment explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that resulted in certain subsidiaries and business divisions of The Vanguard Group reporting ownership separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Insulet Corporation announced a voluntary medical device correction for specific lots of its Omnipod® 5 Pods in the U.S. after identifying a manufacturing issue that can cause small tears in internal tubing and under-delivery of insulin.
The company has received 18 reports of serious adverse events tied to high blood glucose and diabetic ketoacidosis, but no deaths, and has notified the FDA. The affected lots represent about 1.5% of annual Omnipod 5 pod production, and Insulet does not expect shipment or new-patient-start disruptions. Customers can check lot numbers online and obtain free replacement Pods.
Insulet currently expects to incur up to $40 million of related costs in 2026, which will be excluded from adjusted results, and it is not changing previously issued 2026 guidance.
Insulet Corporation reported entering into a severance agreement and release with former Chief Financial Officer Ana M. Chadwick. The agreement implements severance and other post-termination benefits that were already disclosed under prior arrangements and the company’s Amended and Restated Executive Severance Plan.
The filing explains that the Severance Agreement does not add or change any material compensation or benefits terms. It includes standard provisions such as a release of legal claims, mutual non-disparagement, and requirements that Ms. Chadwick comply with existing executive severance and confidentiality, non-solicit, non-compete, and intellectual property assignment agreements.
INSULET CORP senior vice president Prem Singh reported routine share dispositions related to tax withholding on vested equity. On February 27, 2026, a total of 269 shares of common stock were withheld at $246.61 per share to cover tax obligations from restricted stock units vesting. These transactions are coded as tax-withholding dispositions, not open-market sales, and Singh continued to hold several thousand shares directly afterward.
INSULET CORP senior vice president Laetitia Cousin reported small share disposals tied to tax withholding, not open-market selling. On the vesting of restricted stock units, 200 and 53 shares of common stock were withheld at a price of $246.61 per share to cover associated tax obligations. After these transactions, she directly held 5,674 shares of Insulet common stock.
INSULET CORP executive reports tax-related share withholdings
Insulet Corp Group VP, CAO and Controller Lauren Budden reported two Form 4 transactions on common stock dated February 27, 2026. The transactions were coded "F," meaning shares were withheld to satisfy tax obligations upon vesting of restricted stock units, rather than open-market sales.
Budden had 119 shares and 99 shares withheld at a reference price of $246.61 per share to cover associated taxes. Following these non-market dispositions, she directly holds 8,526 shares of Insulet common stock.
Insulet Corp SVP and General Counsel John W. Kapples reported routine share withholding to cover taxes on vested stock awards. On February 27, 2026, 411 and 194 shares of Insulet common stock were disposed of at $246.61 per share through tax-withholding transactions.
According to the filing, these dispositions were for tax obligations tied to restricted stock units vesting, rather than open-market sales. After these transactions, Kapples directly held 27,514 shares of Insulet common stock.